Market Analysis and Price Projections for the Drug NDC: 00093-0787
Understanding the National Drug Code (NDC)
The National Drug Code (NDC) 00093-0787 identifies a specific drug product, in this case, atenolol tablets, which are used to treat hypertension. The NDC includes the labeler code, product code, and package code, providing detailed information about the drug, its manufacturer, and packaging[2].
Drug Overview
Atenolol tablets, identified by NDC 00093-0787, are prescribed to lower blood pressure and reduce the risk of fatal and non-fatal cardiovascular events. They are manufactured by Teva Pharmaceuticals USA, Inc.[1].
Market Analysis
Generic vs. Branded Drugs
Atenolol is a generic drug, which places it within the commodity-like generic drug industry. This sector is characterized by intense competition, mid-single-digit percent annual price erosion, and modest revenue growth. Generic drugs face significant competition, which can limit profitability despite substantial revenue growth[2].
Competitive Landscape
The market for atenolol tablets is highly competitive, with multiple manufacturers such as Mylan, Sandoz, and Teva Pharmaceutical Industries. This competition drives prices down and influences market dynamics[4].
Pricing Dynamics
Competition
The presence of multiple generic versions of atenolol tablets drives prices down. For instance, if several companies produce the same drug, they must compete on price to gain market share[2].
Regulatory Environment
FDA inspections and potential price-fixing litigation can impact pricing strategies. Ensuring compliance with FDA regulations is crucial for maintaining market presence and avoiding disruptions[2].
Market Demand
The demand for atenolol, driven by the prevalence of hypertension and other cardiovascular conditions, can influence pricing. Increasing demand for drugs treating chronic conditions can support higher sales volumes despite price erosion[2].
Price Projections
Current Pricing Trends
In the generic drug market, prices are expected to erode annually by mid-single-digit percentages. This trend is consistent with the current outlook for the pharmaceutical industry, where revenue growth is modest but stable[2].
Future Pricing
Given the competitive nature of the generic drug market, here are some key points to consider for future price projections:
- Annual Price Erosion: Expect prices to decrease by around 3-5% annually due to market competition and regulatory pressures.
- Revenue Growth: Despite price erosion, the overall revenue for generic drugs may still grow modestly due to increased volume and market penetration.
- Cost Recovery: Companies will need to balance their pricing to cover costs, including distribution, marketing (if applicable), and earning a reasonable return on investment[2].
Example Scenario
If the atenolol tablets corresponding to NDC 00093-0787 are priced at $100 per unit currently, here is a possible price projection over the next few years:
| Year |
Price per Unit |
| 2024 |
$100 |
| 2025 |
$95 |
| 2026 |
$90.25 |
| 2027 |
$85.74 |
| 2028 |
$81.36 |
This scenario assumes an annual price erosion of about 5%, which is within the expected range for generic drugs[2].
Market Drivers and Risks
Drivers
- Increasing Demand: If the prevalence of hypertension and other cardiovascular conditions increases, demand for atenolol could rise, supporting higher sales volumes despite price erosion.
- Regulatory Compliance: Ensuring compliance with FDA regulations can help maintain market presence and avoid disruptions[2].
Risks
- Price-Fixing Litigation: Ongoing or potential litigation related to price-fixing can impact pricing strategies and profitability.
- FDA Inspections: Increased inspections of foreign manufacturing facilities can lead to compliance issues and potential market disruptions[2].
Distribution and Marketing
The distribution and marketing strategies for atenolol tablets can also influence their pricing. For instance, if the company does not engage in direct-to-consumer marketing or paid advertising, costs can be kept lower, allowing for more competitive pricing[2].
Impact of Regulatory Changes
The Medicare Drug Price Negotiation Program, set to take effect in 2026, may also impact the pricing of atenolol tablets. Negotiated prices under this program could further reduce the cost of the drug for Medicare beneficiaries, potentially influencing market prices[5].
Key Takeaways
- Pricing Trends: Expect annual price erosion in the range of 3-5% due to market competition.
- Revenue Growth: Modest revenue growth is anticipated despite price erosion.
- Cost Management: Companies must balance pricing to cover costs and earn a reasonable return on investment.
- Regulatory Compliance: Ensuring compliance with FDA regulations is crucial for maintaining market presence.
- Market Demand: Increasing demand for drugs treating chronic conditions can support higher sales volumes.
FAQs
Q: What is the primary use of atenolol tablets identified by NDC 00093-0787?
A: Atenolol tablets are primarily used to treat hypertension and lower blood pressure, reducing the risk of fatal and non-fatal cardiovascular events[1].
Q: Who are the major manufacturers of atenolol tablets?
A: Major manufacturers include Mylan, Sandoz, and Teva Pharmaceutical Industries[4].
Q: What factors influence the pricing of generic drugs like atenolol?
A: Pricing is influenced by competition, regulatory environment, and market demand[2].
Q: How much can prices be expected to erode annually for generic drugs like atenolol?
A: Prices are expected to decrease by around 3-5% annually due to market competition and regulatory pressures[2].
Q: What are the potential risks in the market for atenolol tablets?
A: Potential risks include price-fixing litigation and FDA inspections of manufacturing facilities[2].
Sources
- DailyMed: Atenolol tablet - DailyMed.
- DrugPatentWatch: Latest drug prices and trends for NDC 00093-7664.
- Intelligencia.ai: 2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch.
- ASHP: Drug Shortage Detail: Atenolol tablets.
- CMS: Medicare Drug Price Negotiation Program - CMS.
